Navigation Links
Luminex Corporation Reports Third Quarter 2010 Results
Date:11/4/2010

ein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)Contacts:

Harriss T. Currie

Matthew ScaloVice President, Finance and Chief Financial Officer

Sr. Director of Investor Relations512-219-8020

512-219-8020hcurrie@luminexcorp.com

mscalo@luminexcorp.com LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)September 30,December 31,20102009(unaudited)ASSETSCurrent assets:Cash and cash equivalents

$
79,229$
90,843Restricted cash

1,001-Short-term investments

27,9398,511Accounts receivable, net

19,01322,108Inventories, net

24,13617,524Deferred income taxes

2,7751,040Prepaids and other

2,6262,130Total current assets

156,719142,156Property and equipment, net

21,22817,255Intangible assets, net

13,42712,938Deferred income taxes

10,61014,732Long-term investments

11,12020,228Goodwill

42,06239,617Other

3,8721,087Total assets

$
259,038$
248,013LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
,878$
8,430Accrued liabilities

6,3367,493Deferred revenue

4,3462,967Current portion of long term debt

593868Other

33-Total current liabilities

18,18619,758Long-term debt

3,4043,591Deferred revenue

4,4734,6
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
2. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
3. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
4. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
5. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
6. Luminex Corporation to Present at UBS Global Life Sciences Conference
7. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
8. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
9. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
10. Gentris Corporation Names New Chief Scientific Advisor
11. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ALBANY, New York , July 27, 2015 ... Transparency Market Research "Bionics Market - Global Industry Analysis, Size, ... market was valued at USD 7.96 billion in 2014, growing ... account for USD 20.49 billion in 2021. The ... in the number of accidents, which is leading to paralysis ...
(Date:7/27/2015)... , July 20, 2015 Research and ... of the "D-dimer Testing Market - Global ... Forecast 2014 - 2022" report to their ... vitro diagnostics market is one of the fastest ... attributed to the improved health care awareness, preference ...
(Date:7/27/2015)... July 27, 2015 The Physician-Patient Alliance for Health ... PPAHS posted its first blog on July 27, 2011, " ... ". This post featured what happened to ... of a grocery store in Goodhue, Minnesota ... marathon involving 20 others, who took turns pumping his chest. ...
Breaking Medicine Technology:Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3Physician-Patient Alliance for Health & Safety Turns 4 Years Old 2
... at American Society of Clinical Oncology 2009 Annual Meeting ... , , SAN FRANCISCO, June 2 Medivation, ... presentation of new clinical results from a Phase 1-2 ... castration-resistant prostate cancer (CRPC) patients. The new findings, ...
... , Panel Discussant Focuses on Longer Duration of Remission ... Complete Remissions Achieved with Standard Chemotherapy , , ... MTA: CTIC) announced today that at the poster and ... Section at the 2009 American Society of Clinical Oncology ...
Cached Medicine Technology:Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 2Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 3Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 4Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 2Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 3Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 4Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 6
(Date:7/28/2015)... ... July 28, 2015 , ... VAZATA, a ... expanding their cloud presence to support their rapidly growing business. , Headquarted in ... been serving the Dallas/Fort Worth area for almost 50 years. HeartPlace is recognized ...
(Date:7/28/2015)... ... 2015 , ... Please join us for the 5th Annual Step for Hope 5K Run/Walk ... Avenue and Lies Road in Carol Stream. All are welcome. , Now in its ... and help to support individuals and families affected by a brain aneurysm. , “We ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... a number of publications, including Runner’s World Magazine, is plantar fasciitis . ... constant pain. , Designed by a professional athletic trainer, the Zensah Ankle ...
(Date:7/28/2015)... ... July 28, 2015 , ... Intellitec Solutions has been named by ... of Value Added Resellers of ERP Software is a look at the firms that ... honor represents the second such award in 2015 for Intellitec Solutions, following being named ...
(Date:7/28/2015)... Saint Louis, MO (PRWEB) , ... July 28, 2015 , ... ... and back pain comes in as a close second. Clients suffering from headaches and ... help clients get started with chiropractic treatment, The Joint 's nine offices in ...
Breaking Medicine News(10 mins):Health News:HeartPlace Announces Cloud Expansion with VAZATA 2Health News:HeartPlace Announces Cloud Expansion with VAZATA 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2Health News:The Joint St. Louis Offers “2 for Thursday” Special, Chiropractic Care Services, Affordable Back Pain Relief 2
... who receive compounds that stimulate white blood cell production ... an increased// risk of developing a type of leukemia ... new study in the February 7 Journal of the ... risk of the conditions is very small, but that ...
... remains a dreaded disease even today. But whether patients survive ... much they can afford to spend// on the drugs, according ... to ration life-saving cancer treatment, and some Canadians will live ... said the Cancer Advocacy Coalition of Canada report. ...
... found that wisdom in old age depends on a fresh ... that when mature mice learn a new task, their newly ... old ones, the New Scientist reported on its website. ... the Hospital for Sick Children in Toronto, Canada, injected a ...
... that video games that contain high levels of action, such ... ,Researchers at the University of Rochester have shown that people ... day over the course of a month improved by about ... visual acuity test similar to ones used in regular ophthalmology ...
... A recent survey identifies teen’s online behavior associated ... strangers online are more likely to become// victims ... personal information on the Internet. The report was ... Pediatrics & Adolescent Medicine, one of the JAMA/Archives ...
... in the on-line journal PLoS Biology concluded that the low ... central nervous system to// prematurely shut down. ... molecular trigger for the effects of toxicant exposure, may give ... new methods of evaluating the safety of chemicals. ...
Cached Medicine News:Health News:Growth Factors Given With Chemotherapy may Increase Risk of Blood Diseases 2Health News:Growth Factors Given With Chemotherapy may Increase Risk of Blood Diseases 3Health News:Call for a National 'Drugs Funding Program' for Cancer Treatment in Canada 2Health News:Action Video Games Improves Vision 2Health News:Teens More Likely to Become Victims of Online Harassments 2Health News:Environmental Toxicants Target Stem Cells 2Health News:Environmental Toxicants Target Stem Cells 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 6 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 7.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 6.0 mm and length 10 mm....
Medicine Products: